| Name | Title | Contact Details |
|---|
InfiMed, Inc. is a Liverpool, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syntheon, Endoscopy Division is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repro-Med Systems, Inc., operating as RMS Medical products, is a leading developer and manufacturer of medical devices and supplies. Repro-Med was incorporated in March, 1980. Its stock is publicly traded in the over-the-counter market and is quoted through the National Daily Quotation Service. Its stock symbol is REPR. The company maintains offices, manufacturing facilities, and warehouse space in Chester, New York. Devices and supplies manufactured and sold by RMS Medical Products are subject to Food and Drug Administration regulation. Our manufacturing facilities and record-keeping must meet FDA standards, and are subject to periodic FDA inspection. In addition, the company's plant is certified by the appropriate ISO international standards for quality in product development, manufacturing, distribution and customer support of its medical devices. RMS manufactures medical devices used in emergency care, hospital settings, nursing homes, other medical facilities and home care. The Company's principal products are the FREEDOM60 Syringe Infusion System and the RES-Q-VAC Emergency Medical Suction System. In 2011, the company received FDA approval to market in the U.S. it's HIgH-Flo RMS Subcutaneous Needle Sets. Since 1986, the company has owned and marketed the Gyneco product line which includes the Masterson Endometrial Biopsy Kit used for in-office biopsy sampling procedures, and the Thermal Cautery System used for tubal ligation procedures. RMS maintains its own sales staff in addition to selling its products through distributors in the U.S. and many other countries. It regularly exhibits at both national and international trade shows. The company holds a number of patents related to products it has developed and is manufacturing. Because Repro-Med Systems, Inc., is a public company, it must comply with financial reporting and other regulations established by the Securities and Exchange Commission.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.
xiqi biomedical instrument co.,ltd is a Taizhou, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.